Temporal trends in transfusion-transmitted cytomegalovirus infection among cytomegalovirus-seronegative HSCT recipients
Year: 2026
Type: article
Study design: Observational Study
Abstract: BACKGROUND: The incidence of transfusion-transmitted cytomegalovirus (TT-CMV) after hematopoietic stem cell transplantation (HSCT) in the era of universal leukoreduction remains unclear. This study evaluated temporal changes in TT-CMV and clinically significant CMV infection (csCMVi) in Japan. METHODS: Data from 5,016 CMV-seronegative HSCT recipients registered between 1999 and 2022 were retrospectively analyzed. TT-CMV was defined as CMV antigenemia and/or CMV disease, and csCMVi as the initiation of pre-emptive therapy or CMV disease. RESULTS: Random donor (RD) blood products were independently associated with TT-CMV (odds ratio 2.35, 95% confidence interval 1.75-3.15, P < 0.001) and csCMVi (subdistribution hazard ratio 2.22, 95% CI 1.67-2.96, P < 0.001). Among allogeneic HSCT recipients receiving RD blood products, TT-CMV decreased from 25.7% in 2007-2020 to 12.7% in 2021-2022, while the 100-day cumulative incidence of csCMVi decreased from 24.7% to 8.3% over the same periods. During 2021-2022, differences between RD and CMV-seronegative donor blood products were not statistically significant. CMV disease incidence did not differ between groups. CONCLUSIONS: TT-CMV and csCMVi decreased substantially over time. Although RD blood products remained associated with higher overall risk, the additional benefit of CMV-seronegative blood products may be limited under contemporary transfusion practices.
Authors: Kimikazu Yakushijin, Takahiro Fukuda, Masao Ogata, Sachiko Seo, Ryu Yanagisawa, Michiko Kajiwara, Naoyuki Uchida, Youko Suehiro, Noriko Doki, Yoshinobu Kanda, Masatsugu Tanaka, Mineo Kurokawa, Daiichiro Hasegawa, Motoshi Ichikawa, Nobuhiro Tsukada, Yoshiyuki Takahashi, Satoshi Yoshihara, Satoshi Okada, Shinichi Ito, Shingo Yano, Makoto Onizuka, Fumihiko Ishimaru, Yoshiko Atsuta, Hideki Nakasone, the Transplant Complications Working Group. of the Japanese Society for Transplantation and Cellular Therapy (JSTCT)
Institutions: Kobe University Hospital, National Cancer Center Hospital, Oita University, Oita University Hospital, Tokyo Women's Medical University, Shinshu University Hospital, Institute of Science Tokyo Hospital, Toranomon Hospital, National Hospital Organization Kyushu Cancer Center, Tokyo Metropolitan Komagome Hospital, Jichi Medical University Saitama Medical Center, Saitama Medical University, Kanagawa Cancer Center, University of Tokyo Hospital, The University of Tokyo, Kobe Children's Hospital, NTT Medical Center, Japanese Red Cross Medical Center, Nagoya University, Hyogo Medical University, Hyogo Medical University Hospital, Hiroshima University, Hakodate Municipal Hospital, Jikei University School of Medicine, Tokai University, Tokai University Hospital, Japanese Red Cross Society, Japan, Aichi Medical University, The Japanese Data Center for Hematopoietic Cell Transplantation, Jichi Medical University
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,390
OpenAlex ID: W7222316532